BR0215192A - Development factor modified protein matrices for tissue construction - Google Patents
Development factor modified protein matrices for tissue constructionInfo
- Publication number
- BR0215192A BR0215192A BR0215192-8A BR0215192A BR0215192A BR 0215192 A BR0215192 A BR 0215192A BR 0215192 A BR0215192 A BR 0215192A BR 0215192 A BR0215192 A BR 0215192A
- Authority
- BR
- Brazil
- Prior art keywords
- matrix
- heparin
- drug
- protein
- regeneration
- Prior art date
Links
- 238000010276 construction Methods 0.000 title 1
- 102000035118 modified proteins Human genes 0.000 title 1
- 108091005573 modified proteins Proteins 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229920000669 heparin Polymers 0.000 abstract 3
- 229960002897 heparin Drugs 0.000 abstract 3
- 238000011069 regeneration method Methods 0.000 abstract 3
- 238000012377 drug delivery Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000008929 regeneration Effects 0.000 abstract 2
- 230000017423 tissue regeneration Effects 0.000 abstract 2
- 108010000196 Factor XIIIa Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000007838 tissue remodeling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g. rapidly near the living tissue interface and more slowly farther into the injury zone. Additional benefits include the lower total drug dose within the delivery system, and spatial regulation of release which permits a greater percentage of the drug to be released at the time of greatest cellular activity.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/024,918 US20020168718A1 (en) | 1997-04-03 | 2001-12-18 | Enzyme-mediated modification of fibrin for tissue engineering |
| PCT/EP2002/012458 WO2003040235A1 (en) | 2001-11-07 | 2002-11-07 | Synthetic matrix for controlled cell ingrowth and tissue regeneration |
| US10/323,046 US7601685B2 (en) | 1998-08-27 | 2002-12-17 | Growth factor modified protein matrices for tissue engineering |
| PCT/US2002/041114 WO2003052091A1 (en) | 2001-12-18 | 2002-12-18 | Growth factor modified protein matrices for tissue engineering |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0215192A true BR0215192A (en) | 2005-04-26 |
| BRPI0215192B1 BRPI0215192B1 (en) | 2016-03-22 |
| BRPI0215192B8 BRPI0215192B8 (en) | 2021-07-27 |
Family
ID=27807134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0215192A BRPI0215192B8 (en) | 2001-12-18 | 2002-12-18 | fusion peptide, kit and matrix comprising the same, and method for creating a matrix |
Country Status (9)
| Country | Link |
|---|---|
| JP (2) | JP4560291B2 (en) |
| AT (1) | ATE386545T1 (en) |
| AU (2) | AU2002358272B2 (en) |
| BR (1) | BRPI0215192B8 (en) |
| CA (1) | CA2470419A1 (en) |
| DE (1) | DE60225185T2 (en) |
| ES (1) | ES2301697T3 (en) |
| MX (1) | MXPA04006021A (en) |
| WO (1) | WO2003052091A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
| EP1830863A2 (en) * | 2004-12-10 | 2007-09-12 | Straumann Holding AG | Protein formulation |
| EP1862170B1 (en) | 2004-12-10 | 2012-03-14 | Straumann Holding AG | Enamel formulation with amelogenin |
| SE0403014D0 (en) | 2004-12-10 | 2004-12-10 | Straumann Holding Ag | New protein formulation |
| CA2592040A1 (en) * | 2004-12-22 | 2006-06-29 | Kuros Biosurgery Ag | Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| EP3111966B1 (en) * | 2005-01-06 | 2021-10-13 | Kuros Biosurgery AG | Supplemented matrices for the repair of bone fractures |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| CA2930681C (en) | 2007-04-09 | 2019-10-15 | The Board Of Trustees Of The University Of Arkansas | Fusion protein of collagen-binding domain and parathyroid hormone |
| JP2010523243A (en) | 2007-04-13 | 2010-07-15 | クロス・バイオサージェリー・アクチェンゲゼルシャフト | Polymer tissue sealant |
| US20100284919A1 (en) * | 2007-10-12 | 2010-11-11 | Kuros Biosurgery Ag | Injectable Radio-Opaque Compositions for Tissue Augmentation |
| ES2403057T3 (en) | 2008-04-18 | 2013-05-13 | Kuros Biosurgery Ag | Supply device, kit containing the device, and method of operating the device |
| WO2011025957A2 (en) * | 2009-08-28 | 2011-03-03 | Ecole Polytechnique Federal De Lausanne | Tg-aprotinin fusion proteins and matrices thereof |
| KR101922741B1 (en) * | 2011-02-03 | 2019-02-20 | 노스이스턴 유니버시티 | Methods and compositions for highly specific capture and release of biological materials |
| ES2882852T3 (en) | 2011-03-16 | 2021-12-02 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
| WO2013120060A1 (en) | 2012-02-09 | 2013-08-15 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
| ES2975215T3 (en) | 2011-12-14 | 2024-07-04 | Univ Arkansas | Delivery of therapeutic agents via a collagen-binding protein |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| JP5918909B2 (en) * | 2012-06-25 | 2016-05-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Targeted therapeutics |
| DK3347061T3 (en) * | 2015-09-09 | 2021-08-23 | Eth Zuerich | Injectable macroporous hydrogels |
| US11624060B2 (en) | 2017-02-10 | 2023-04-11 | The Board Of Trustees Of The University Of Arkansas | Collagen-binding agent compositions and methods of using the same |
| EP3536353A1 (en) | 2018-03-09 | 2019-09-11 | Kuros Biosurgery AG | Method and kits for producing a fibrin matrix |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171670A (en) * | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
| US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| WO1997018314A1 (en) * | 1995-11-16 | 1997-05-22 | Boehringer Mannheim Gmbh | Process for the preparation of peptides by way of streptavidin fusion proteins |
| HUP0100075A2 (en) * | 1997-12-18 | 2001-05-28 | Eli Lilly And Co. | Crystalline teriparatide |
| WO2000044808A1 (en) * | 1999-02-01 | 2000-08-03 | Hubbell Jeffrey A | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| JP2001190280A (en) * | 1999-02-19 | 2001-07-17 | Terumo Corp | Collagen-binding physiologically active polypeptide |
-
2002
- 2002-12-18 DE DE60225185T patent/DE60225185T2/en not_active Expired - Lifetime
- 2002-12-18 JP JP2003552958A patent/JP4560291B2/en not_active Expired - Lifetime
- 2002-12-18 AT AT02792510T patent/ATE386545T1/en not_active IP Right Cessation
- 2002-12-18 BR BRPI0215192A patent/BRPI0215192B8/en not_active IP Right Cessation
- 2002-12-18 MX MXPA04006021A patent/MXPA04006021A/en active IP Right Grant
- 2002-12-18 ES ES02792510T patent/ES2301697T3/en not_active Expired - Lifetime
- 2002-12-18 CA CA002470419A patent/CA2470419A1/en not_active Abandoned
- 2002-12-18 WO PCT/US2002/041114 patent/WO2003052091A1/en active IP Right Grant
- 2002-12-18 AU AU2002358272A patent/AU2002358272B2/en not_active Expired
-
2009
- 2009-01-13 JP JP2009005240A patent/JP2009102383A/en active Pending
- 2009-04-21 AU AU2009201588A patent/AU2009201588B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002358272A1 (en) | 2003-06-30 |
| BRPI0215192B8 (en) | 2021-07-27 |
| DE60225185T2 (en) | 2009-02-19 |
| AU2009201588A1 (en) | 2009-05-14 |
| JP2005517658A (en) | 2005-06-16 |
| MXPA04006021A (en) | 2005-08-19 |
| ES2301697T3 (en) | 2008-07-01 |
| DE60225185D1 (en) | 2008-04-03 |
| JP2009102383A (en) | 2009-05-14 |
| JP4560291B2 (en) | 2010-10-13 |
| WO2003052091A8 (en) | 2003-08-07 |
| CA2470419A1 (en) | 2003-06-26 |
| ATE386545T1 (en) | 2008-03-15 |
| AU2002358272B2 (en) | 2009-01-22 |
| AU2009201588B2 (en) | 2011-02-24 |
| WO2003052091A1 (en) | 2003-06-26 |
| BRPI0215192B1 (en) | 2016-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0215192A (en) | Development factor modified protein matrices for tissue construction | |
| DE60042795D1 (en) | MATRICES FROM MODIFIED GROWTH FACTORS FOR TISSUE CONSTRUCTION | |
| Pan et al. | Advances in the repair of segmental nerve injuries and trends in reconstruction | |
| Hao et al. | Collagen/heparin bi‐affinity multilayer modified collagen scaffolds for controlled bFGF release to improve angiogenesis in vivo | |
| Weber et al. | The effects of cell–matrix interactions on encapsulated β-cell function within hydrogels functionalized with matrix-derived adhesive peptides | |
| JP6144249B2 (en) | Polypeptide-polymer conjugates and methods of use thereof | |
| Singh et al. | Delivery of VEGF using collagen‐coated polycaprolactone scaffolds stimulates angiogenesis | |
| Holloway et al. | Synergistic Effects of SDF‐1α and BMP‐2 Delivery from Proteolytically Degradable Hyaluronic Acid Hydrogels for Bone Repair | |
| Park et al. | The possibility of microbial cellulose for dressing and scaffold materials | |
| Madzovska-Malagurski et al. | Towards antimicrobial yet bioactive Cu-alginate hydrogels | |
| Gelberman et al. | The early effects of sustained platelet-derived growth factor administration on the functional and structural properties of repaired intrasynovial flexor tendons: an in vivo biomechanic study at 3 weeks in canines | |
| Gelberman et al. | Effect of adipose‐derived stromal cells and BMP12 on intrasynovial tendon repair: a biomechanical, biochemical, and proteomics study | |
| WO2003065881A3 (en) | Medical device with coating that promotes endothelial cell adherence and differentiation | |
| WO2010060104A3 (en) | Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration | |
| BRPI0613401B8 (en) | ophthalmic composition comprising glucocorticoid derivatives that selectively penetrate posterior segment tissues | |
| WO2007062060A3 (en) | Methods and compositions using substance p to promote wound healing | |
| De Cock et al. | Layer-by-layer incorporation of growth factors in decellularized aortic heart valve leaflets | |
| ATE392907T1 (en) | BIOABSORBABLE COMPOSITE MATERIALS MADE OF DERIVATIZED HYALURONIC ACID | |
| Doǧan et al. | Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo | |
| Chinen et al. | Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release | |
| Sun et al. | Crosslinking heparin to collagen scaffolds for the delivery of human platelet‐derived growth factor | |
| BR112021019520A2 (en) | Pharmaceutical composition, method for treating hunter syndrome and use of a pharmaceutical composition | |
| Draenert et al. | BMP‐2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials | |
| Chen et al. | The fabrication of double-layered chitosan/gelatin/genipin nanosphere coating for sequential and controlled release of therapeutic proteins | |
| WO2016060252A1 (en) | Implant material for nerve regeneration, method for manufacturing implant material for nerve regeneration, and kit for manufacturing implant material for nerve regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 9/10 Ipc: A61K 38/29 (2006.01), A61K 33/06 (2006.01), C07K 1 |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/03/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2002, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 18/12/2022 |